Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Coherus BioSciences, Inc. (CHRS : NSDQ)
 
 • Company Description   
Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.

Number of Employees: 332

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.60 Daily Weekly Monthly
20 Day Moving Average: 1,096,082 shares
Shares Outstanding: 77.42 (millions)
Market Capitalization: $588.41 (millions)
Beta: 1.20
52 Week High: $19.32
52 Week Low: $7.41
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -27.69% -20.77%
12 Week -38.31% -33.06%
Year To Date -52.38% -43.37%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
333 TWIN DOLPHIN DRIVE SUITE 600
-
REDWOOD CITY,CA 94065
USA
ph: 650-649-3530
fax: -
ir@coherus.com http://www.coherus.com
 
 • General Corporate Information   
Officers
Dennis M. Lanfear - Chairman;President and Chief Executive Officer
McDavid Stilwell - Chief Financial Officer
Lee Nisley Newcomer - Director
Ali J. Satvat - Director
Mark D. Stolper - Director

Peer Information
Coherus BioSciences, Inc. (CORR.)
Coherus BioSciences, Inc. (RSPI)
Coherus BioSciences, Inc. (CGXP)
Coherus BioSciences, Inc. (BGEN)
Coherus BioSciences, Inc. (GTBP)
Coherus BioSciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 19249H103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 77.42
Most Recent Split Date: (:1)
Beta: 1.20
Market Capitalization: $588.41 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.98 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.77 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 46.78
Price/Cash Flow: -
Price / Sales: 1.94
EPS Growth
vs. Year Ago Period: 47.68%
vs. Previous Quarter: -106.67%
Sales Growth
vs. Year Ago Period: -27.60%
vs. Previous Quarter: -18.07%
ROE
03/31/22 - -211.68
12/31/21 - -224.13
09/30/21 - -133.21
ROA
03/31/22 - -30.54
12/31/21 - -40.24
09/30/21 - -30.72
Current Ratio
03/31/22 - 1.02
12/31/21 - 3.64
09/30/21 - 2.10
Quick Ratio
03/31/22 - 0.86
12/31/21 - 3.42
09/30/21 - 1.98
Operating Margin
03/31/22 - -69.24
12/31/21 - -87.92
09/30/21 - -63.72
Net Margin
03/31/22 - -69.24
12/31/21 - -87.92
09/30/21 - -63.72
Pre-Tax Margin
03/31/22 - -69.24
12/31/21 - -87.92
09/30/21 - -63.42
Book Value
03/31/22 - 0.16
12/31/21 - 1.27
09/30/21 - 1.71
Inventory Turnover
03/31/22 - 1.13
12/31/21 - 1.38
09/30/21 - 1.32
Debt-to-Equity
03/31/22 - -
12/31/21 - 4.18
09/30/21 - 2.16
Debt-to-Capital
03/31/22 - -
12/31/21 - 80.69
09/30/21 - 68.31
 

Powered by Zacks Investment Research ©